Efficacy Analysis of Tigecycline-based Therapy and Polymyxin B-based Therapy in ICU Infection (NCT04970537) | Clinical Trial Compass
UnknownNot Applicable
Efficacy Analysis of Tigecycline-based Therapy and Polymyxin B-based Therapy in ICU Infection
China800 participantsStarted 2017-07-23
Plain-language summary
The gender, age, ICU diagnosis, basic diseases, antibiotic treatment plan, physiological indicators, duration of hospital stay, length of stay in ICU, hospitalization cost, prognosis and other discharge information of patients receiving tigecycline or polymyxin B admitted to the ICU of four provincial-level Grade A hospitals in Changsha, Hunan Province ,China from 2017 to 2021 were included.
To analyze the therapeutic effect of tigecycline-based or polymyxin B-based antibiotic regimens and their effect on the prognosis of patients, and to conduct subgroup analysis.
Who can participate
Age range
18 Years – 95 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* ICU patients receiving tigecycline or polymyxin B treatment;
* Age 14-95, gender unlimited;
* there are clear infections and strains;
* The patient and/or his/her family agree to sign the informed consent voluntarily.
Exclusion Criteria:
* Patients with treatment of less than 4 days;
* patients with abscission;
* Pregnant patients;
* Patients with age \< 14 years or \> 95 years.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
hospital mortality rate
Timeframe: up to hospital discharge or die in hospital, up to 48 weeks(estimation).
2
30d mortality rate
Timeframe: up to the 30th day of the treatment of tigecycline or polymyxin B
3
Bacterial clearance rate
Timeframe: from the first day of the treatment of tigecycline or polymyxin B until to the end day, up to 8 weeks (estimation).
Trial details
NCT IDNCT04970537
SponsorXiangya Hospital of Central South University